Ignite Creation Date:
2025-12-24 @ 7:36 PM
Ignite Modification Date:
2025-12-31 @ 9:33 AM
Study NCT ID:
NCT05227703
Status:
COMPLETED
Last Update Posted:
2025-10-28
First Post:
2022-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-05
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-09-11
Completion Date Type:
ACTUAL
First Submit Date:
2022-01-27
First Submit QC Date:
None
Study First Post Date:
2022-02-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-09-05
Results First Submit QC Date:
None
Results First Post Date:
2025-10-28
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2025-10-28
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2025-10-14
Last Update Post Date:
2025-10-28
Last Update Post Date Type:
ESTIMATED